Atossa Therapeutics (ATOS) 10-Q 13 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 09, 2019
Document Information [Line Items]
Entity Registrant Name	ATOSSA GENETICS INC
Entity Central Index Key	0001488039
Trading Symbol	atos
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		9,124,732
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 19,568,247	$ 10,380,493
Restricted cash	110,000	110,000
Prepaid expenses	835,468	509,833
Research and development tax rebate receivable	237,856	518,098
Other current assets	27,957	30,942
Total current assets	20,779,528	11,549,366
Furniture and equipment, net	48,212	54,487
Intangible assets, net	91,667	99,375
Right-of-use asset	88,103
Other assets	17,218	17,218
Total Assets	21,024,728	11,720,446
Current liabilities
Accounts payable	463,970	353,328
Accrued expenses	74,844	177,074
Payroll liabilities	891,758	935,070
Stock-based compensation liability		1,410,025
Lease liability	50,706
Other current liabilities	9,863	39,939
Total current liabilities	1,491,141	2,915,436
Long term liabilities
Lease liability long term	37,397
Total Liabilities	1,528,538	2,915,436
Commitments and contingencies (note 11)
Stockholders' equity
Preferred stock - $0.001 par value; 10,000,000 shares authorized; 702 and 2,379 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	1	2
Additional paid-in capital- Series B convertible preferred stock	701,999	2,378,997
Common stock - $0.18 par value; 175,000,000 shares authorized, and 9,122,171 and 5,846,552 shares issued and outstanding, as of March 31, 2019 and December 31, 2018, respectively	1,641,979	1,052,372
Additional paid-in capital	98,056,781	82,204,902
Accumulated deficit	(80,904,570)	(76,831,263)
Total Stockholders' Equity	19,496,190	8,805,010
Total Liabilities and Stockholders' Equity	$ 21,024,728	$ 11,720,446

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	702	2,379
Preferred stock, outstanding (in shares)	702	2,379
Common stock, par value (in dollars per share)	$ 0.18	$ 0.18
Common stock, authorized (in shares)	175,000,000	175,000,000
Common stock, issued (in shares)	9,122,171	5,846,552
Common stock, outstanding (in shares)	9,122,171	5,846,552

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating expenses
Research and development	$ 1,451,236	$ 470,976
General and administrative	2,613,093	1,403,465
Total operating expenses	4,064,329	1,874,441
Operating loss	(4,064,329)	(1,874,441)
Other income (expense)	(8,978)	59
Loss before income taxes	(4,073,307)	(1,874,382)
Income taxes	0	0
Net loss	$ (4,073,307)	$ (1,874,382)
Loss per common share - basic and diluted (in dollars per share)	$ (0.62)	$ (8.48)
Weighted average shares outstanding - basic and diluted (in shares)	6,565,514	220,996

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock Additional Paid-in Capital [Member]Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017			220,996
Balance at Dec. 31, 2017			$ 477,342	$ 71,887,674	$ (65,426,329)	$ 6,938,687
Amortization of commitment shares				(19,852)		(19,852)
Compensation cost for stock options granted				215,139		215,139
Net loss					(1,874,382)	(1,874,382)
Balance (in shares) at Mar. 31, 2018			220,996
Balance at Mar. 31, 2018			$ 477,342	72,082,961	(67,300,711)	5,259,592
Balance (in shares) at Dec. 31, 2018	2,379		5,846,552
Balance at Dec. 31, 2018	$ 2	2,378,997	$ 1,052,372	82,204,902	(76,831,263)	8,805,010
Amortization of commitment shares
Compensation cost for stock options granted				275,833		275,833
Net loss					(4,073,307)	$ (4,073,307)
Issuance of common stock upon warrant exercise (in shares)			2,799,188			2,800,000
Issuance of common stock upon warrant exercise			$ 503,854	10,832,856		$ 11,336,710
Conversion of Series B convertible preferred stock to common stock (in shares)	(1,677)
Conversion of Series B convertible preferred stock to common stock	$ (1)
Conversion of Series B convertible preferred stock to common stock		(1,676,998)	$ 85,753	1,591,246
Conversion of Series B convertible preferred stock to common stock (in shares)			476,431
Reclassification of stock-based liability awards to equity upon cancellation				3,151,944		3,151,944
Balance (in shares) at Mar. 31, 2019	702		9,122,171
Balance at Mar. 31, 2019	$ 1	$ 701,999	$ 1,641,979	$ 98,056,781	$ (80,904,570)	$ 19,496,190

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudied) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,073,307)	$ (1,874,382)
Adjustments to reconcile net loss to net cash used in operating activities
Compensation cost for stock options granted	275,833	215,139
Depreciation and amortization	13,983	7,864
Change in fair value of stock-based compensation liability	1,741,919
Changes in operating assets and liabilities:
Prepaid expenses	(325,635)	(244,723)
Research and development tax rebate receivable	280,242	(37,595)
Other assets	2,985	51,512
Accounts payable	110,642	(166,554)
Payroll liabilities	(43,312)	(428,440)
Accrued expenses	(102,230)	82,508
Other current liabilities	(30,076)	7,789
Net cash used in operating activities	(2,148,956)	(2,386,882)
CASH FLOWS FROM INVESTING ACTIVITY
Purchase of furniture and equipment		(51,068)
Net cash used in investing activities		(51,068)
CASH FLOWS FROM FINANCING ACTIVITY
Proceeds from exercise of warrants	11,336,710
Net cash provided by financing activities	11,336,710
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	9,187,754	(2,437,950)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	10,490,493	7,272,469
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	19,678,247	4,834,519
SUPPLEMENTAL DISCLOSURES
Cash and cash equivalents	19,568,247	4,779,519
Restricted cash	110,000	55,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	19,678,247	4,834,519
NONCASH INVESTING AND FINANCING ACTIVITIES
Reclassification of stock-based liability awards to equity upon cancellation	3,151,944
Amortization of commitment shares		$ 19,852

Note 1 - Nature of Operations

Note 1 - Nature of Operations	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1: Atossa Genetics Inc. (the “Company”) was incorporated on April 30, 2009 December 31.

Note 2 - Liquidity and Capital

Note 2 - Liquidity and Capital Resources	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2: The Company has incurred net losses and negative operating cash flows since inception. For the three March 31, 2019, $4.1 $2.1 March 31, 2019, $19.6 $19.3 not one not may not may

Note 3 - Summary of Accounting

Note 3 - Summary of Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	NOTE 3: Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2018. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three March 31, 2019, not may December 31, 2019. Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements: In the first 2019, No. 2016 02, Lease Accounting 842 : (" 842 ") $101,000 not not 840. 2018 10 840. not not not not not not 11, Commitments and Contingencies, On January 1, 2019, 2018 08, Not 958 not 958 not Recent Accounting Pronouncements: In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 820, 3 December 15, 2019. not

Note 4 - Prepaid Expenses

Note 4 - Prepaid Expenses	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Prepaid Expenses [Text Block]	NOTE 4: Prepaid expenses consisted of the following: March 31, December 31, 2019 2018 Prepaid insurance $ 234,875 $ 160,576 Prepaid research and development 392,894 218,090 Professional services 96,250 110,094 Financial exchange fees 58,685 Prepaid rent 17,100 Retainer and security deposits 14,218 16,718 Other 21,446 4,355 Total prepaid expenses $ 835,468 $ 509,833

Note 5 - Research and Developme

Note 5 - Research and Development Tax Rebate Receivable	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Research and Development Tax Rebate Receivable [Text Block]	NOTE 5: On May 23, 2017, 1 2 $0.435 three March 31, 2019 2018, $80,000 $86,000, $35,000 $38,000 three March 31, 2019 2018, March 31, 2019, $238,000 $203,000 December 31, 2018.

Note 6 - Payroll Liabilities

Note 6 - Payroll Liabilities	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 6: Payroll liabilities consisted of the following: March 31, 2019 December 31, 2018 Accrued bonuses $ 646,433 $ 697,995 Accrued vacation 162,619 160,740 Accrued payroll 82,706 76,335 Total payroll liabilities $ 891,758 $ 935,070

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7: The Company is authorized to issue a total of 185,000,000 175,000,000 $0.18 10,000,000 $0.001 750,000 $0.001 4,000 $0.001 25,000 $0.001 No no March 31, 2019. 2018 On May 30, 2018, 13,624 13,624 3,869,216 one $4.05 “2018 $12.3 Warrants As of March 31, 2019, 1,070,028 $4.05 May 30, 2022. For the three March 31, 2019, $11.3 2018 2.8 2.8 Conversion of Series B Convertible Preferred Stock During the three March 31, 2019, 1,677 476,431 284

Note 8 - Net Loss Per Share

Note 8 - Net Loss Per Share	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 8: The Company accounts for and discloses net loss per common share in accordance with ASC Topic 260, Earnings Per Share The following table summarizes the Company’s calculation of net loss per common share: Three Months Ended March 31, 2019 2018 Numerator Net loss attributable to common shareholders $ (4,073,307 ) $ (1,874,382 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 6,565,514 220,996 Net loss per share of common stock, basic and diluted: $ (0.62 ) $ (8.48 ) The following table sets forth the number of potential common shares excluded from the calculation of net loss per diluted share for the three March 31, 2019 2018 Three Months Ended March 31, 2019 2018 Options to purchase common stock 783,383 14,473 Series B convertible preferred stock 458,994 Warrants to purchase common stock 3,369,468 76,235 4,611,845 90,708

Note 9 - Income Taxes

Note 9 - Income Taxes	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 9: Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not As a result of the Company’s cumulative losses, management has concluded that a full valuation allowance against the Company’s net deferred tax assets is appropriate. No March 31, 2019 December 31, 2018,

Note 10 - Concentration of Cred

Note 10 - Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 10: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. March 31, 2019 December 31, 2018, $18,925,000 $10,052,000

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11: Lease Commitments As discussed in Note 3, No. 2016 02, Lease Accounting: 842 , January 1, 2019. January 1, 2019, 840, Leases 842, not Our operating lease assets consist of an office lease and a copier system lease. Our office lease expires in August 2020 October 2021. None three March 31, 2019, $12,900 March 31, 2019, 1.7 12%. As of March 31, 2019, $44,000, $44,000 $12,000 2019, 2020 2021, $12,000 three March 31, 2019 $14,600. Litigation and Contingencies We are subject to legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not

Note 12 - Stock Based Compensat

Note 12 - Stock Based Compensation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 12: Stock Option and Incentive Plan On September 28, 2010, 2010 “2010 may 2010 September 2020. No may 2010 10 5,556 2010 May 18, 2016, 11,111 2010 May 9, 2018, 125,000 2010 April 12, 2018, 500,000 2010 The following table presents the automatic additions to the 2010 2010 January 1, Number of 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 7,257 2017 12,623 2018 106,076 2019 233,862 Total additional shares 374,782 The Company did not three March 31, 2019 2018. No three March 31, 2019 2018. 236,430 2010 March 31, 2019. Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options, over the requisite service period, or vesting period. Accordingly, the Company recognized stock-based compensation expense of $275,833 $215,139 three March 31, 2019 2018, Three Months Ended March 31, 2019 2018 General and administrative $ 224,676 $ 166,701 Research and development 51,157 48,438 Total stock compensation Expense $ 275,833 $ 215,139 Options issued and outstanding as of March 31, 2019, 2010 three Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2019 783,383 $ 12.14 Granted Forfeited Expired Outstanding as of March 31, 2019 783,383 12.14 8.92 $ 695,400 Exercisable as of March 31, 2019 434,515 19.38 8.84 $ 374,063 Vested and expected to vest 783,383 $ 12.14 8.92 $ 695,400 At March 31, 2019, 348,868 $876,533. 1.40 2018 On June 27, 2018, 2,300,000 700,000 2010 2010 January 13, 2019, The Liability Options were exercisable for shares of common stock at an exercise price of $2.38 ten not not The Liability Options were subject to vesting requirements. Twenty- five 50% two 25% January 13, 2019, January 13, 2019, 1,125,000 Compensation costs associated with the Liability Options were initially recognized, based on the grant-date fair values of these options, over the requisite or vesting period for time-based options or when it is probable the performance criteria were achieved for options that vest based on performance. Compensation cost was remeasured each period based on the market value of our underlying stock until award vesting or settlement. At the time of cancellation, the fair value of Liability Options at January 13, 2019, January 13, 2019 Risk free interest rate 2.53 % Expected term (in years) 4.50-5.00 Stock price $ 1.36 Dividend yield % Expected volatility 121.0-123.0 % As a result of the cancellation, the Company recognized all remaining unrecognized compensation expense related to these options of $1,741,919, Period Ended March 31, 2019 General and administrative $ 1,074,183 Research and development 667,736 Total stock compensation expense $ 1,741,919 Also on January 13, 2019, 2,300,000 800,000 “2019 2019 $1.36 not 2010 January 13, 2019, 2019 2010 2019 not 2010 2018 2019 not 2019 The above actions were unanimously approved by the disinterested members of the Board of Directors. The above actions are intended to eliminate the Company’s potential liability associated with the net cash exercise provision of the liability options, and to allow the stockholders of the Company the opportunity to vote on the Amended Plan, which includes shares issuable upon exercise of the 2019 Accounting treatment Awards offered under a plan that are subject to shareholder approval are not may not 2019 2019 not 718. not no January 13, 2019, $1,741,919 2018 $3,151,944 2019 718.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation: The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10 10 01 X. not no 10 December 31, 2018. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three March 31, 2019, not may December 31, 2019.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements: In the first 2019, No. 2016 02, Lease Accounting 842 : (" 842 ") $101,000 not not 840. 2018 10 840. not not not not not not 11, Commitments and Contingencies, On January 1, 2019, 2018 08, Not 958 not 958 not Recent Accounting Pronouncements: In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 820, 3 December 15, 2019. not

Note 4 - Prepaid Expenses (Tabl

Note 4 - Prepaid Expenses (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	March 31, December 31, 2019 2018 Prepaid insurance $ 234,875 $ 160,576 Prepaid research and development 392,894 218,090 Professional services 96,250 110,094 Financial exchange fees 58,685 Prepaid rent 17,100 Retainer and security deposits 14,218 16,718 Other 21,446 4,355 Total prepaid expenses $ 835,468 $ 509,833

Note 6 - Payroll Liabilities (T

Note 6 - Payroll Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2019 December 31, 2018 Accrued bonuses $ 646,433 $ 697,995 Accrued vacation 162,619 160,740 Accrued payroll 82,706 76,335 Total payroll liabilities $ 891,758 $ 935,070

Note 8 - Net Loss Per Share (Ta

Note 8 - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2019 2018 Numerator Net loss attributable to common shareholders $ (4,073,307 ) $ (1,874,382 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 6,565,514 220,996 Net loss per share of common stock, basic and diluted: $ (0.62 ) $ (8.48 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2019 2018 Options to purchase common stock 783,383 14,473 Series B convertible preferred stock 458,994 Warrants to purchase common stock 3,369,468 76,235 4,611,845 90,708

Note 12 - Stock Based Compens_2

Note 12 - Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	January 1, Number of 2012 2,502 2013 2,871 2014 4,128 2015 5,463 2016 7,257 2017 12,623 2018 106,076 2019 233,862 Total additional shares 374,782
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2019 2018 General and administrative $ 224,676 $ 166,701 Research and development 51,157 48,438 Total stock compensation Expense $ 275,833 $ 215,139 Period Ended March 31, 2019 General and administrative $ 1,074,183 Research and development 667,736 Total stock compensation expense $ 1,741,919
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Weighted- Weighted- Aggregate Outstanding as of January 1, 2019 783,383 $ 12.14 Granted Forfeited Expired Outstanding as of March 31, 2019 783,383 12.14 8.92 $ 695,400 Exercisable as of March 31, 2019 434,515 19.38 8.84 $ 374,063 Vested and expected to vest 783,383 $ 12.14 8.92 $ 695,400
Liability Options [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	January 13, 2019 Risk free interest rate 2.53 % Expected term (in years) 4.50-5.00 Stock price $ 1.36 Dividend yield % Expected volatility 121.0-123.0 %

Note 2 - Liquidity and Capita_2

Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Net Income (Loss) Attributable to Parent, Total	$ (4,073,307)	$ (1,874,382)
Net Cash Provided by (Used in) Operating Activities, Total	(2,148,956)	(2,386,882)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	19,568,247	$ 4,779,519	$ 10,380,493
Working Capital	$ 19,300,000

Note 3 - Summary of Accountin_2

Note 3 - Summary of Accounting Policies (Details Textual) - USD ($)	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Liability, Total		$ 101,000
Operating Lease, Right-of-Use Asset	$ 88,103	$ 101,000

Note 4 - Prepaid Expenses - Sch

Note 4 - Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Prepaid insurance	$ 234,875	$ 160,576
Prepaid research and development	392,894	218,090
Professional services	96,250	110,094
Financial exchange fees	58,685
Prepaid rent	17,100
Retainer and security deposits	14,218	16,718
Other	21,446	4,355
Total prepaid expenses	$ 835,468	$ 509,833

Note 5 - Research and Develop_2

Note 5 - Research and Development Tax Rebate Receivable (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	May 23, 2017
Research and Development Expense, Total	$ 1,451,236	$ 470,976
Increase (Decrease) in Research and Development Tax Rebate Receivable	(280,242)	37,595
Research and Development Tax Rebate Receivable	237,856		$ 518,098
Atossa Genetics AUS Pty Ltd [Member]
Research and Development Cash Rebate per Dollar				$ 0.435
Research and Development Expense, Total	80,000	86,000
Increase (Decrease) in Research and Development Tax Rebate Receivable	35,000	$ 38,000
Research and Development Tax Rebate Receivable	$ 238,000		$ 203,000

Note 6 - Payroll Liabilities -

Note 6 - Payroll Liabilities - Schedule of Payroll Liabilities (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Accrued bonuses	$ 646,433	$ 697,995
Accrued vacation	162,619	160,740
Accrued payroll	82,706	76,335
Total payroll liabilities	$ 891,758	$ 935,070

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	May 30, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Number of Shares Authorized to Issue		185,000,000
Common Stock, Shares Authorized		175,000,000		175,000,000
Common Stock, Par or Stated Value Per Share		$ 0.18		$ 0.18
Preferred Stock, Shares Authorized		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total		702		2,379
Class of Warrant or Right, Outstanding		1,070,028
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.05
Proceeds from Warrant Exercises		$ 11,336,710
Class of Warrant or Right, Exercised During Period		2,800,000
Stock Issued During Period, Shares, Warrant Exercised		2,800,000
Preferred Stock, Shares Outstanding, Ending Balance		702		2,379
Conversion of Series B Convertible Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Converted		1,677
Conversion of Stock, Shares Issued		476,431
Convertible Preferred Stock, Shares Issued upon Conversion		284
The 2018 Subscription Rights Offering [Member]
Number of Units Sold	13,624
Proceeds from Issuance of Stock units	$ 12,300,000
The 2018 Subscription Rights Offering [Member] | The 2018 Warrants [Member]
Class of Warrant or Right, Outstanding	3,869,216
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.05
Series A Junior Participating Preferred Stock [Member]
Preferred Stock, Shares Authorized		750,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Issued, Total		0
Series A Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		4,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Shares Outstanding, Ending Balance		0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized		25,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Series B Convertible Preferred Stock [Member] | The 2018 Subscription Rights Offering [Member]
Stock Issued During Period, Shares, New Issues	13,624

Note 8 - Net Loss Per Share - S

Note 8 - Net Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net loss attributable to common shareholders	$ (4,073,307)	$ (1,874,382)
Weighted average shares outstanding - basic and diluted (in shares)	6,565,514	220,996
Loss per common share - basic and diluted (in dollars per share)	$ (0.62)	$ (8.48)

Note 8 - Net Loss Per Share -_2

Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Number of potential common shares excluded (in shares)	4,611,845	90,708
Share-based Payment Arrangement, Option [Member]
Number of potential common shares excluded (in shares)	783,383	14,473
Series B Convertible Preferred Stock [Member]
Number of potential common shares excluded (in shares)	458,994
Warrant [Member]
Number of potential common shares excluded (in shares)	3,369,468	76,235

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Expense (Benefit), Total	$ 0	$ 0

Note 10 - Concentration of Cr_2

Note 10 - Concentration of Credit Risk (Details Textual) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Cash, Uninsured Amount	$ 18,925,000	$ 10,052,000

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)	3 Months Ended
	Mar. 31, 2019USD ($)
Operating Lease, Expense	$ 12,900
Operating Lease, Weighted Average Remaining Lease Term	1 year 255 days
Operating Lease, Weighted Average Discount Rate, Percent	12.00%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 44,000
Lessee, Operating Lease, Liability, Payments, Due Year Two	44,000
Lessee, Operating Lease, Liability, Payments, Due Year Three	12,000
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	12,000
Operating Lease, Payments	$ 14,600

Note 12 - Stock Based Compens_3

Note 12 - Stock Based Compensation (Details Textual) - USD ($)	Jan. 13, 2019	Jun. 27, 2018	May 09, 2018	Apr. 12, 2018	May 18, 2016	Sep. 28, 2010	Mar. 31, 2019	Mar. 31, 2018
Adjustments to Additional Paid in Capital, Transfer of Stock-based Compensation Liability Upon Option Cancellation	$ 3,151,944						$ 3,151,944
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense							$ 275,833	$ 215,139
Liability Options [Member]
Share-based Payment Arrangement, Expense	$ 1,741,919
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance	1,125,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 2.38
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Liability Options [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Liability Options [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Liability Options [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Liability Options [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		2,300,000
Liability Options [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		700,000
The 2019 Options [Member[
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.36
The 2019 Options [Member[ | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,300,000
The 2019 Options [Member[ | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	800,000
The 2010 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Period for Granting Shares						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period								0
The 2010 Stock Option and Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						5,556
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			125,000	500,000	11,111
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							236,430
Share-based Payment Arrangement, Expense							$ 275,833	$ 215,139
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance							348,868
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount							$ 876,533
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition							1 year 146 days

Note 12 - Stock Based Compens_4

Note 12 - Stock Based Compensation - Additional Shares Authorized (Details) - shares	3 Months Ended	12 Months Ended							87 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2019
The 2010 Stock Option and Incentive Plan [Member]
Total additional shares (in shares)	233,862	106,076	12,623	7,257	5,463	4,128	2,871	2,502	374,782

Note 12 - Stock Based Compens_5

Note 12 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)	Jan. 13, 2019	Mar. 31, 2019	Mar. 31, 2018
Liability Options [Member]
Total stock compensation expense	$ 1,741,919
Share-based Payment Arrangement, Option [Member]
Total stock compensation expense		$ 275,833	$ 215,139
General and Administrative Expense [Member] | Liability Options [Member]
Total stock compensation expense	1,074,183
General and Administrative Expense [Member] | Share-based Payment Arrangement, Option [Member]
Total stock compensation expense		224,676	166,701
Research and Development Expense [Member] | Liability Options [Member]
Total stock compensation expense	$ 667,736
Research and Development Expense [Member] | Share-based Payment Arrangement, Option [Member]
Total stock compensation expense		$ 51,157	$ 48,438

Note 12 - Stock Based Compens_6

Note 12 - Stock Based Compensation - Stock Option Activity (Details) - The 2010 Stock Option and Incentive Plan [Member]	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Outstanding, shares (in shares) | shares	783,383
Outstanding, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 12.14
Outstanding, shares (in shares) | shares	783,383
Outstanding, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 12.14
Outstanding, weighted average contractual life remaining in years (Year)	8 years 335 days
Outstanding, aggreate instrinsic value | $	$ 695,400
Exercisable, shares (in shares) | shares	434,515
Exercisable, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 19.38
Exercisable, weighted average contractual life remaining in years (Year)	8 years 306 days
Exercisable, aggreate instrinsic value | $	$ 374,063
Vested and expected to vest, shares (in shares) | shares	783,383
Vested and expected to vest, Weighted average exercise price per share (in dollars per share) | $ / shares	$ 12.14
Vested and expected to vest, weighted average contractual life remaining in years (Year)	8 years 335 days
Vested and expected to vest, aggreate instrinsic value | $	$ 695,400

Note 12 - Stock Based Compens_7

Note 12 - Stock Based Compensation - Valuation Assumptions for Liability Options (Details)	Jan. 13, 2019$ / shares
Dividend yield
Liability Options [Member]
Risk free interest rate	2.53%
Stock price (in dollars per share)	$ 1.36